Clinical Trial Search

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…

Primary: Rate of Immunological Response to Vaccination — 0; 15 participants

Primary: Complete Response (CR) Rate — 0.68 proportion

Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants

Primary: Maximum Tolerated Dose of Bortezomib (Phase I) — 1.3 mg/m^2

Primary: Number of Participants With Toxicity — 8 participants

Primary: Two-year Disease-free Survival — 90 percentage of participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants

Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants

Primary: Progression-Free Survival (PFS) — 8 years

Primary: Progression-free Survival Rate at 18 Months — 88.5; 96 percentage of participants

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Progression-free Survival — 90 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of Bortezomib — 1.5; 1.0 mg/m²

Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…

Primary: Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR). — 90…

Primary: Correlation Coefficient Between Change From Baseline in Fluoro-L-thymidine Positron Emission Tomography (FLT-PET) Maximum Standard Uptake Value (SUVmax) and in…

Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Progression-Free Survival (PFS) at 2 Years — 82; 81 percentage of participants

Primary: Progression Free Survival Rate (PFS) at 2 Years Post-Blood or Marrow Transplant (BMT) — 73.5 percentage of participants

Primary: Overall Response Rate (ORR) — 31.8; 0; 7.7 percentage of participants

Primary: Overall Response Rate (ORR) As Assessed By Independent Review Committee — 72 Participants — p=<.0001